INmune Bio, Inc. (INMB) Stock Forecast
INMB analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.67 / 5 from 3 analysts
- Price target
- $7.00 average of analyst targets
- Upside to target
- +345.9% from the latest close
- Next earnings
- October 29, 2026 EPS estimate $-0.18
- 52-week range
- $1.12 – $2.51
INMB analyst ratings
3 analystsNumber of analysts at each rating.
INMB price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
INMB earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.18 | −$0.20 | −$0.17 | −$0.24 | +22.9% | 2 |
| Current fiscal year (2026) | −$0.55 | −$0.67 | −$0.43 | −$1.19 | +53.7% | 2 |
| Next fiscal year (2027) | −$0.43 | −$0.43 | −$0.43 | −$0.55 | +21.8% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
INMB revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 3 |
| Current fiscal year (2026) | $0 | $0 | $0 | −100.0% | 3 |
| Next fiscal year (2027) | $9.5M | $3.9M | $15.2M | 0.0% | 2 |
INMB EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
INMB revenue: reported and forecast
INMB EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.17 | −$0.17 | −$0.18 | −$0.18 | −$0.18 | +12.1% | 1 up · 0 down |
| Current fiscal year (2026) | −$0.60 | −$0.43 | −$0.55 | −$0.55 | −$0.55 | −8.8% | 2 up · 0 down |
| Next fiscal year (2027) | −$0.53 | −$0.53 | −$0.49 | −$0.49 | −$0.43 | −18.1% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
INMB earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; INMB beat in 7 of 12.
What analysts expect from INMB
3 analysts cover INmune Bio; their consensus rating is strong buy (4.67 on a 1–5 scale, where 5 is a strong buy). The average price target is $7.00, 345.9% above the latest close of $1.57. Analysts expect earnings of −$0.55 per share for 2026, +53.7% from a year earlier. For 2027 the average estimate is −$0.43 per share on revenue of $9.5 million. INmune Bio beat the EPS estimate in 7 of the last 12 quarters.
Related: INMB income statement, INMB key metrics, INMB chart. See the INMB stock overview for the latest quote and news.
INMB forecast FAQ
What is INmune Bio's price target?
The average analyst price target for INmune Bio is $7.00, 345.9% above the latest close of $1.57.
Is INmune Bio a buy, hold or sell?
Of 3 analysts covering INmune Bio, 2 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is INmune Bio's EPS forecast?
Analysts forecast −$0.55 per share for 2026 (range −$0.67 to −$0.43); for 2027 the estimate is −$0.43.
When does INmune Bio report earnings?
INmune Bio is expected to report results for the quarter ending September 30, 2026 on October 29, 2026 after the market closes; the EPS estimate is $-0.18.
Does INmune Bio usually beat earnings estimates?
INmune Bio reported EPS at or above the analyst estimate in 7 of the last 12 quarters.